Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

enGene Therapeutics Inc

ENGN ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.70

▲ +0.59%

Market Cap $113.88M · Vol 291.33K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$113.88M

Micro Cap

Div Yield

N/A

EPS Growth

+23.80%

YoY

RSI (14)

42.50

Momentum

Beta

-0.29

vs Market

52W High

$12.24

86.11% below

52W Low

$1.41

21.00% above

Volume

291.33K

Avg 243.14K

P/B

2.24

Price-to-book

ROE

-53.28%

Return on equity

Free Float

91.20%

Public shares

Shariah Compliance8 STANDARDS

✗ enGene Therapeutics Inc (ENGN) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ENGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.56%

-10.29%

-6.08%

-82.62%

YTD

-81.17%

-52.91%

-84.47%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-117,302,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-53.28%
ROA · ROIC	-44.05% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.24
P/FCF	N/A
EPS Growth	+23.80%
Outstanding Shares	66.99M

Technical Indicators

50-Day SMA	$1.78
200-Day SMA	$6.05
RSI (14)	42.50
Beta	-0.29
52-Week High	$12.24
52-Week Low	$1.41

Volume Today	291.33K
Avg Daily Volume (30D)	243.14K
Relative Volume	1.20x
Volatility (10D)	42.05
Volatility (30D)	46.15
Free Float	91.20%

Analyst Consensus

BUY

Current Price $1.70

Mean Target $8.28

52W Low$1.41 52W High$12.24

Current

Target

$1.41 $12.24

Current Analyst target

+386.93% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01J1GCYX6

ISINCA29286X1015

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateSep 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).